Using MCA to Manage Breast Cancer
Author Information
Author(s): V. Laurence, M.A. Forbes, E.H. Cooper
Primary Institution: Cookridge Hospital, Leeds, UK
Hypothesis
The study investigates the relationship between serum MCA levels and the clinical status of breast cancer patients.
Conclusion
MCA is a useful marker for monitoring treatment in patients with local recurrence and metastatic breast cancer.
Supporting Evidence
- Only 6% of patients with Stage I-III disease had raised MCA levels after surgery.
- 77% of patients with metastases had raised MCA levels.
- Concordance between MCA level changes and clinical status was 64% for local recurrence and 84% for metastatic disease.
Takeaway
Doctors can use a blood test for a marker called MCA to see how well breast cancer treatments are working.
Methodology
Serum samples were collected from 233 breast cancer patients and analyzed for MCA levels in relation to their clinical status.
Limitations
Patient information was not available at the time of serum marker assay, and the study relied on coded samples.
Participant Demographics
231 women and 2 men with breast cancer.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website